CLINICAL TRIALS PROFILE FOR COMMIT
✉ Email this page to a colleague
All Clinical Trials for Commit
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000895 ↗ | A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | The purpose of this study is to determine if infection with Mycobacterium avium complex (MAC) occurs in other parts of the body before it is found in the blood. This study also evaluates the relationships between the amount of HIV in the blood, immune system functions, and the presence of MAC infection. HIV-positive patients are at risk for MAC infection because their immune systems have been weakened by HIV. It is hoped that aggressive treatment with anti-HIV drugs may improve their immune systems enough to prevent against MAC. |
| NCT00074737 ↗ | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | Completed | Eleos, Inc. | Phase 2 | 2004-04-01 | The principal goal of this clinical trial is to assess the ability of cenersen sodium (EL625) to improve cancer responsiveness to the established AML therapeutic agent Idarubicin used alone or in combination with Cytarabine (Ara-C). Cenersen sodium is a drug that is designed to block the effects of a protein called p53. Laboratory evidence shows that blocking p53 will make many types of cancer, including acute myelogenous leukemia (AML), more sensitive to a variety of established cancer therapeutics while making normal tissues more resistant to the toxic effects of these agents. |
| NCT00132899 ↗ | COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) | Completed | Schering-Plough | Phase 3 | 2005-12-01 | The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent enough to require corticosteroid therapy. |
| NCT00132899 ↗ | COMMIT (Combination Of Maintenance Methotrexate-Infliximab Trial) | Completed | University of Western Ontario, Canada | Phase 3 | 2005-12-01 | The primary objective is to compare the efficacy and safety of infliximab plus methotrexate to infliximab alone for the long-term control of signs and symptoms of Crohn's disease (CD) in patients with symptoms that are persistent enough to require corticosteroid therapy. |
| NCT00174993 ↗ | Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes | Completed | Eli Lilly and Company | Phase 3 | 2001-05-01 | The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes. |
| NCT00174993 ↗ | Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes | Completed | Takeda | Phase 3 | 2001-05-01 | The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with type 2 diabetes. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Commit
Condition Name
Clinical Trial Locations for Commit
Trials by Country
Clinical Trial Progress for Commit
Clinical Trial Phase
Clinical Trial Sponsors for Commit
Sponsor Name
